tbuckley/cabot-search huggingface dataset:
10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial
Authors: N. Girard, W. Li, A. Spira, J. Feldman, M. Mak, M.B. Sauder, F. Bozorgmehr, P-J. Voon, C.T. Yang, J. Cundom, J.J. Nieva, P. Tomasini, I. Cicin, T. Romero, S. Sheng, J. Bauml, J. Simões, P. Mahadevia, M. Wildgust, B.C. Cho
Journal: Journal of Thoracic Oncology (2025)
12P: Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small cell lung cancer (sqNSCLC): 5y update from the phase III CameL-sq trial
Authors: C. Zhou, S. Ren, J. Chen, X. Xu, Y. Cheng, G. Chen, Y. Pan, Y. Fang, Q. Wang, Y. Huang, W. Yao, R. Wang, X. Li, W. Zhang, Y. Zhang, S. Hu, R-H. Guo, D. Wang, Z. Wang, X. Lu
Journal: Journal of Thoracic Oncology (2025)
6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
Authors: S.R. Punekar, D.S. Hong, J. Luo, S-H.I. Ou, M.L. Johnson, A. Spira, I. Garrido-Laguna, J.W. Goldman, B. Herzberg, A. Saltos, P. Mitra, A. Hegde, R. Vora, M. Hiremath, K.C. Arbour
Journal: Journal of Thoracic Oncology (2025)
3O: Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts
Authors: N. Girard, H.H.F. Loong, B-C. Goh, P.A. Jänne, X. Dong, S. Novello, S. Lu, G. Daniele, H.R. Kim, T-Y. Yang, K. Goto, J. Zhao, D.S.W. Tan, L. Li, A. Prelaj, Y. Fang, M. Ghadessi, P. Grassi, X. Le, T.M. Kim
Journal: Journal of Thoracic Oncology (2025)
48P: Real-world evaluation of ipilimumab (Ipi)/nivolumab (Nivo) in combination with two cycles of chemotherapy in patients (pts) with programmed death-ligand (PD-L1) negative advanced non-small cell lung cancer (aNSCLC): Interim results of the RW-9LA study
Authors: L. Decoster, S. Vande Kerckhove, E. Ravoet, F. Vervenne, K. Vekens
Journal: Journal of Thoracic Oncology (2025)
53P: Characterisation of benefit-risk by pemetrexed (pem) exposure in patients (pts) with EGFRm aNSCLC treated with 1L osimertinib (osi) + platinum-pem in FLAURA2
Authors: D. Planchard, Y. Cheng, K. Kobayashi, H. Mann, Y. Rukazenkov, C.K. Lee, N. Valdiviezo, J.C-H. Yang, D. Ghiorghiu, P.A. Jänne
Journal: Journal of Thoracic Oncology (2025)
52P: Does timing of immunotherapy infusion influence clinical outcomes in non-small cell lung cancer?
Authors: I. Furtado, R.Q. Ferreira, M.A. Montenegro, J.L. Mendes, R. Escaleira, F. Verdasca, M. Seladas, A.J. Fernandes, N. Duarte, L.M. Coelho, S. Alfarroba, I. Guerreiro
Journal: Journal of Thoracic Oncology (2025)
45P: Extended follow-up confirmed real-world efficacy and safety of cemiplimab monotherapy in advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression
Authors: S. Masini, R. Alvarez Cabellos, I. De Elejoste Echebarria, M. Martinez Kareaga, M. Antonanzas Basa, M.C. Escoin Perez, F. Navarro, C. Traseira Puchol, L. Cabezon Gutierrez, S. Falagán Martínez, C. Garcia Benito, L. Masfarre Pinto, C. Avila Andrade, S. Sequero, J. Mosquera Martinez, E. Garcia Lorenzo, A. Azkárate Martínez, L. Paz-Ares, J. Zugazagoitia, J. Baena Espinar
Journal: Journal of Thoracic Oncology (2025)
41P: Network meta-analysis (NMA) of the first-line therapy for advanced non-squamous non-small cell lung cancer (nsNSCLC): Does PD-L1 expression modify effect of the immunotherapy on the overall survival (OS)?
Authors: M. Fedyanin, O. Mironenko, N. Sableva, A. Lazarev, D. Tolkacheva, K.V. Sapozhnikov
Journal: Journal of Thoracic Oncology (2025)
42P: First-line (1L) nivolumab (N) + ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): Interim data from the German non-interventional study (NIS) FINN
Authors: C.C. Schumann, D.M. Behringer, J.B. Kuon, P. Sadjadian, W. Blau, A. Hassler, S. Wilop, M.K. Welslau, C. Ziske, D. Flieger, S. Kreher, M. Groschek, G. Hübner, A. Althoff, I. Dittrich, M. Link, T. Bluhmki, D. Waldenberger, S. Gütz, E. von der Heyde
Journal: Journal of Thoracic Oncology (2025)
29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial
Authors: H. Lena, L. Paz-Ares, H. Harputluoglu, E. Wauters, S. Rossi, M. Ozguroglu, C. Helissey, G. Lo Russo, L. Greillier, M.A.N. Sendur, M. D’Arcangelo, H. Kobayashi, A. Martinez Bueno, O. Ozyilkan, M. Gumus, M. Celanovic, Y. Mekhloufi, E. Nadal
Journal: Journal of Thoracic Oncology (2025)
40P: Metformin plus/minus cyclic fasting mimicking diet to improve the efficacy of first-line chemo-immunotherapy in advanced LKB1-inactive NSCLC: Results of the phase II trial FAME
Authors: M. Occhipinti, M. Brambilla, G. Di Liberti, C. Proto, A. Prelaj, T. Beninato, M.C. Garassino, P. Ambrosini, S. Manglaviti, L. Mazzeo, C. Vernieri, A. Fabbri, E. Tamborini, F. Galli, D. Signorelli, M.P. Di Palma, S. De Giorgi, F.G.M. De Braud, G. Lo Russo, M. Ganzinelli
Journal: Journal of Thoracic Oncology (2025)
30P: Clinical characteristics and survival outcomes of long-term responders for advanced non-small cell lung cancer patients with first-line PD-1/PD-L1 inhibitors: A multicenter retrospective study
Authors: Z. Du, X. Ge, Y. Li, Y. Qin, H. Fan, Y. Lv, X. Du, Y. Hu, Z. Liu
Journal: Journal of Thoracic Oncology (2025)
44P: First-line chemo-immunotherapy prognostic factors predicting non-small cell lung cancer (NSCLC) overall survival: Multicentric observational study
Authors: R. Ronga, F. Vitiello, F. Ambrosio, B. Miranda, F.J. Romano, G. Viscardi, S. Campione, G. Guggino, A. Vaia, A. Farinaro, P. Maione, C. Gridelli, F. Riccardi
Journal: Journal of Thoracic Oncology (2025)
43P: Phase Ia study of MIDRIX4-LUNG, a tetravalent autologous dendritic cell immunotherapy, in patients with metastatic non-small cell lung cancer
Authors: D. Stevens, J. Ingels, E. Brabants, S. van Lint, C. Everaert, K. Weening, K. Heyns, S. Desmet, P. Devreker, N. Lootens, M. Brusseel, V. Surmont, B. Vandekerckhove, K. Vermaelen
Journal: Journal of Thoracic Oncology (2025)
37P: Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (LA/M nsq-NSCLC): Programmed death-ligand 1 (PD-L1) expression ≥50% subgroup analysis of the randomized, phase III RATIONALE-304 trial
Authors: Y. Yu, M. Wang, J. Wang, X. Yu, Y. Hu, L. Wangjun, X. Li, L. Yuepeng, W. Li, Y. Bao, S. Lu
Journal: Journal of Thoracic Oncology (2025)
38P: Two years of follow-up data of a phase II clinical trial of atezolizumab with bevacizumab for patients with PD-L1 high expression non-squamous non-small cell lung cancer (WJOG10718L/@ Be Study)
Authors: T. Seto, M. Shimokawa, R. Toyozawa, S. Sugawara, H. Hayashi, H. Murakami, T. Kato, S. Niho, M. Oki, H. Yoshioka, H. Daga, K. Azuma, S. Miura, K. Nishino, M. Satouchi, I. Okamoto, N. Yamamoto
Journal: Journal of Thoracic Oncology (2025)
31P: Camrelizumab plus chemotherapy as first-line treatment for advanced non-squamous NSCLC with brain metastases: Final overall survival results from the CAP-BRAIN trial
Authors: X. Hou, C. Zhou, G. Wu, W. Lin, Z. Xie, H-B. Zhang, J. Yi, J. Lv, F. Cheng, C. Ma, L. Chen
Journal: Journal of Thoracic Oncology (2025)
32P: The impact of renal dysfunction and pemetrexed administration dose in KEYNOTE189 on prognosis
Authors: Y. Yamanaka, K. Murotani, H. Yoshioka, K. Fujii, Y. Nagata, Y. Okuno, K. Kamisako, Y. Okazaki, K. Nakanishi, K. Yoshida, T. Ikoma, Y. Takeyasu, U. Katsushima, T. Kurata
Journal: Journal of Thoracic Oncology (2025)
33P: A multi-country time &amp; motion (T&amp;M) study of subcutaneous (SC) vs intravenous (IV) pembrolizumab (Pembro) plus chemotherapy (Chemo) in metastatic non-small cell lung cancer (mNSCLC)
Authors: E. De Cock, S. Oskar, C. Lourdudoss, R. Eiras, C. Pietanza, A. Arunachalam, G.V. Alves, E. Felip
Journal: Journal of Thoracic Oncology (2025)
49P: Phase II study of telomere-targeting agent THIO sequenced by cemiplimab in immune checkpoint inhibitor-resistant advanced NSCLC: Interleukin-6 as a potential predictive biomarker
Authors: T. Jankowski, T. Csoszi, L. Urban, T. Nagy, R. Ramlau, M.D. Cholakova, N. Chilingirova, A.K. Mruk, S. Sótér, K.D. Koynov, M. Kotlarski, M.R. Girotti, I. Mender, M. Vidotto Mitsunaga, O. Tudos, M. Failor, B. Yao, V. Vitoc, S. Gryaznov, V. Zaporojan
Journal: Journal of Thoracic Oncology (2025)
34P: Polymeric micelles paclitaxel (pm-Pac), carboplatin combined with sintilimab in the first-line treatment of advanced non-squamous non-small cell lung cancer(nsq-NSCLC): Phase II study
Authors: Y. Zhou, M. Shi, B. Shen, L. Wang, X. Zhu, X. Li, W. Peng, L. Yan, Y. Tang
Journal: Journal of Thoracic Oncology (2025)
54P: Efficacy and safety of firmonertinib 160 mg combined with intrathecal injection pemetrexed in NSCLC patients with EGFR mutations and leptomeningeal metastases
Authors: X. Li, J. Zhao, Y. Wang, J. Li, L. Li, X. Zheng, J. An, Y. Hua, H. Shi, W. Xu, X. Ding, Q. Wu, Y. Li, B. Cao
Journal: Journal of Thoracic Oncology (2025)
26P: Assessing first-line immunotherapy duration in advanced NSCLC
Authors: S. Rota, R. Serino, P. Ambrosini, T. Beninato, G. Corrao, G. Di Liberti, M. De Ponti, L. Mazzeo, M. Meazza Prina, G. Montelatici, S. Natangelo, A. Prelaj, M. Occhipinti, C. Proto, M. Ganzinelli, A.D. Dumitrascu, C. Bonalume, C. Cavalli, G. Lo Russo, M. Brambilla
Journal: Journal of Thoracic Oncology (2025)
27P: Impact of platinum-based chemotherapy (CT) on acquired resistance (AR) to first-line immunecheckpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC): Individual patient data metanalysis
Authors: S. Oresti, F. Salomone, A. Nuccio, F.R. Ogliari, S.T. Riva, L. Mollica, F.M. Venanzi, M. Ferrara, F. Passaretti, L. Papotto, A. Di Lello, A. Bulotta, B. Ricciuti, R. Califano, M. Di Maio, A. Cortellini, V. Torri, M. Cinquini, G. Viscardi, R. Ferrara
Journal: Journal of Thoracic Oncology (2025)
21P: Primary analysis of safety, efficacy and immunogenicity of the therapeutic cancer vaccine PDC*lung01 with or without pembrolizumab in NSCLC: A multicenter phase I/II study
Authors: J.F. Vansteenkiste, I. Demedts, K. Cuppens, E. Pons-Tostivint, E. Wauters, F.J. Borm, A. Sibille, B. Colinet, M. Pérol, W. Theelen, B. Biesma, C. Van De Kerkhove, E.L. Buchmeier, F.C. Althoff, S. Derijcke, D. Moro-Sibilot, F. Cantero, J. Plumas, F. Renard, M. Skrzypski
Journal: Journal of Thoracic Oncology (2025)
25P: Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase III POSEIDON extended China cohort
Authors: J. Wang, J. Fang, T. Shou, N. Yang, Q. Wang, J. Shi, K. Xiao, W. Zhuang, B. Wang, J. Hu, L. Liu, Y. Yu, Y. Zhang, X. Geng, Y. Zhong, C. Lowery, J. Chen, M.L. Johnson, L. Wang, Z. Chen
Journal: Journal of Thoracic Oncology (2025)
22P: Effects of datopotamab deruxtecan (Dato-DXd) vs docetaxel on patient-reported outcomes (PROs) in adults with previously treated advanced or metastatic non squamous (NSQ) non-small cell lung cancer (NSCLC): Results from TROPION-LUNG01
Authors: R. Cornelissen, E. Pons-Tostivint, M-J. Ahn, Y. Le Guen, E. Felip, N. Girard, I. Okamoto, S. Sugawara, M.H. Hong, V. Westeel, M.A. Cobo Dols, L. Paz-Ares, J. Sands, M. Chargualaf, R. Joseph, F. Diamand, L. Martin, M. Lawrence, A.E. Lisberg
Journal: Journal of Thoracic Oncology (2025)
19P: Subgroup analysis of first-line camrelizumab plus chemotherapy in brain metastases of NSCLC: Results from the CTONG 2003 trial
Authors: Y-S. Li, J-J. Yang, Q. Yu, Q. Bu, L. Lin, F. Ning, G. Wu, G. Lin, A. Zang, S. Ma, C. Zhou, A. Liu, Y. Zhao, C. Wang, Y. Yao, G. Han, J. Zhao, Y. Pan, J. Lv, Y-L. Wu
Journal: Journal of Thoracic Oncology (2025)
82P: A retrospective real-world evidence study of MTAP status and clinical outcomes in patients with advanced non-small cell lung cancer
Authors: A. Sacher, M. Clouser, A. Balasubramanian, E.H. Elkhouly, A. Hindoyan, X. Zhang, B.E. Sylvester, J. Hildebrand, P. Martinez, M. Villalona-Calero
Journal: Journal of Thoracic Oncology (2025)
86P: Diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice: An international ambispective real-world study (OCTOPUS)
Authors: D. Planchard, S. Couraud, C. Mascaux, J.B. Auliac, D.C.C. Christoph, L. Bonomi, A. Chella, E. Carcereny, E. Pons-Tostivint, D. Signorelli, F. Beghdad, O. Dialla, S. Khan, S. Popat
Journal: Journal of Thoracic Oncology (2025)
75P: Firmonertinib plus anlotinib for first-line treatment of advanced EGFR L858R mutated non-small cell lung cancer
Authors: Z. Jin, Y. Zhu, W. Yao, H. Lan, D. Li, C. Zhou, H. Xie, W. Yang, J. Tang, Y. Wang, Y. Liu, L. Kou, J. Ding, X. Li, Y. Sun, F. Yang
Journal: Journal of Thoracic Oncology (2025)
79P: Efficacy outcomes of larotrectinib by prior therapy and performance status in patients with TRK fusion lung cancer
Authors: V. Moreno Garcia, A. Drilon, S. Kummar, J.J. Lin, D.S.W. Tan, D.T. Rieke, B. Dubashi, H. Kunhiparambath, D-I. Burcoveanu, N. Neu, C.E. Mussi, C. Qi
Journal: Journal of Thoracic Oncology (2025)
80P: Final overall survival and long-term safety outcomes of savolitinib in patients with locally advanced or metastatic NSCLC harboring METexon 14 (METex14) mutation: An update from a phase IIIb study
Authors: Y. Yu, Q. Guo, Y. Zhang, J. Fang, D. Zhong, B. Liu, P. Pan, D. Lv, L. Wu, Y. Zhao, J. Li, Z. Liu, C. Liu, Y. Wang, B. Jin, Q. Song, S. Fan, M. Shi, W. Su, S. Lu
Journal: Journal of Thoracic Oncology (2025)
85P: Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC)
Authors: K-L. Koster, A.S.D.F.M. Parreira, H.N. Tan, A. Zachariou, O. Faboyede, S. Venkatesan, M. Parmar, B. Rao Baikady, X. Hu, R. Ruddle, C. Yap, M.D. Forster, S. Popat, J.S. Lopez, J.S. De Bono, A. Sharp, U. Banerji, A. Paschalis, C. Lindsay, A.R. Minchom
Journal: Journal of Thoracic Oncology (2025)
90P: Efficacy of subsequent therapy following the progression of crizotinib in advanced ROS1+ NSCLC in real word setting
Authors: Z. Zou, G. Lin, Z. Liu, B. Cao, D. Huang, T. Lv, Y. Fang, P. Tian, J. Hu, F. Ye, Q. Chu, Y. Xia
Journal: Journal of Thoracic Oncology (2025)
81P: Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes
Authors: Julien Mazieres, R. Veillon, A. Cortot, R. Ferrara, E. Felip, M. Garassino, X. Le, M. Thomas, H. Sakai, E. Smit, J. Raskin, S. Viteri, J.C-H. Yang, M-J. Ahn, Y-L. Wu, J. Zhao, V. Ghori, R. Bruns, A. Johne, P. Paik
Journal: Journal of Thoracic Oncology (2025)
91P: Intracranial efficacy of crizotinib in advanced ROS1+NSCLC in real-world setting
Authors: Z. Zou, G. Lin, B. Cao, D. Huang, T. Lv, M. Shi, Y. Xia, F. Ye, P. Tian, J. Hu, Y. Fang
Journal: Journal of Thoracic Oncology (2025)
83P: Efficacy and safety of lorlatinib in patients with ALK+ metastatic non-small cell lung cancer (mNSCLC) previously treated with an ALK inhibitor: Results from a phase IV study
Authors: A. Bearz, S. Ricciardi, N.V. Raut, M.A. Cobo Dols, S. Chiradoni Thungappa, P.C. Sacco, H. Thurm, D. Pavlov, F. Toffalorio, E. Felip
Journal: Journal of Thoracic Oncology (2025)
87P: Genomic alterations and resistance mechanisms in ALK-rearranged non-small cell lung cancer: Insights from NGS profiling and clinical outcomes
Authors: P. Ambrosini, S. Marchesi, M. Brambilla, S. Rota, R. Serino, C. Cavalli, G. Di Liberti, M. Meazza Prina, F. Perrone, T. Beninato, L. Mazzeo, M. Ganzinelli, G. Corrao, D. Lorenzini, A. Prelaj, C. Proto, F.G.M. De Braud, G. Lo Russo, M. Occhipinti
Journal: Journal of Thoracic Oncology (2025)
88P: Real-world occurrence of early-onset pulmonary events with brigatinib for advanced ALK+ NSCLC
Authors: M.J. Hochmair, G. Stewart, M. Rauter, M. Studnicka, B. Khokhar, R. Gounden, Y. Yin, R. Fram, T. Egenod
Journal: Journal of Thoracic Oncology (2025)
76P: Long-term survival outcomes with first-line (1L) osimertinib monotherapy and subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)
Authors: F. Griesinger, X. Wang, P.S. Karia, M. Cooper, L. Servidio, E. Jedy-Agba, J.J. Nieva, D.B. Doroshow
Journal: Journal of Thoracic Oncology (2025)
96P: Enhanced anti-tumor activity of zelenectide pevedotin in patients (pts) with non-small cell lung cancer (NSCLC) with NECTIN4 gene amplification (amp)
Authors: L. Verlingue, N. Klümper, M. Eckstein, J. Braegelmann, M. McKean, A. Italiano, L. Carter, G.S. Falchook, V. Boni, A. Dowlati, B. Doger De Spéville, E. Fontana, J. Rodon, L. Demars, G. Brown, C. Xu, C. Campbell, T. Gelb, S. Santos, C. Baldini
Journal: Journal of Thoracic Oncology (2025)
95P: Adagrasib (ADA) plus cetuximab (CETUX) in patients (pts) with advanced KRASG12C-mutated non-small cell lung cancer (NSCLC) from KRYSTAL-1
Authors: J. Zhang, A.I. Spira, N.E. Abdulla, M.K. Riaz, S. Sajid, K. Leventakos, K. Doshi, K. He, S.L. McCune, R. Haddad, D. Hakimian, R. Langdon, J.A. Peguero, H.A. Ahmad, N. Brand, M. Chowdhury, L.J. Eccles, M.V. Negrao
Journal: Journal of Thoracic Oncology (2025)
92P: Real-world treatment sequencing and outcomes in ALK-positive metastatic non-small cell lung cancer
Authors: M.F. Dietrich, D. Zala, D. Abrahami, J. Assayag, A. Patel, D. Benjumea, A. Rava, A. Crowley, M. Kent, C. Tsang
Journal: Journal of Thoracic Oncology (2025)
74P: First-line treatment in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC): A review and individual patient data (IPD) comparison of phase III clinical trials
Authors: A. Torchia, A. Sabatini, E. Bengala, M.A. Di Civita, F. Ciurluini, D. Marinelli, M. Giammaruco, A. Laudisi, A.J. Gelibter, G. Minuti, L. Landi, D. Santini, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2025)
101P: European results from the 2024 International Association for the Study of Lung Cancer (IASLC) global survey on biomarker testing
Authors: M.P. Smeltzer, C. Connolly, K. Brunson, M. Chau, S. Chen, A. Kerpel, S. Lantuejoul, A. Mohan, A. Plaxco, J. Rice, U. Basu Roy, R. Santos, R.A. Soo, G. Woodard, M. Wynes, Y. Yatabe, J. King, K. Kelly
Journal: Journal of Thoracic Oncology (2025)
97P: Matching-adjusted indirect comparison (MAIC) of sotorasib vs adagrasib for previously treated advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation
Authors: J. Wolf, D. Chopra, Z. Lan, D.M. Waterhouse, E. Felip, H. Moradian, N. Karim, C. Obiozor, B. Stollenwerk
Journal: Journal of Thoracic Oncology (2025)
98P: Exploratory analysis showed increased overall survival among non-small cell lung cancer (NSCLC) patients with mutated KRAS compared with wildtype KRAS in a phase II trial of mecbotamab vedotin (CAB-AXL-ADC)
Authors: K. Reckamp, G. Dy, E. Yau, J. Rotow, E. Shum, D. Kowalski, M. Alexander, R. Agajanian, J. Zugazagoitia, C. Gay, Y.C.J. Li, L. Villaruz, R.C.Y. Leung, Y-M. Chen, J.J. Nieva, C. Kuzma, J. Fuentes Pradera, K. Chen, K. Aysola, D. Camidge
Journal: Journal of Thoracic Oncology (2025)
94P: Long-term efficacy of lorlatinib vs alectinib in patients with and without brain/central nervous system metastases: Matching-adjusted indirect comparisons
Authors: J. Mazieres, T. Bauer, D. Abrahami, A. Polli, H. Chu, P. Ramachandran, C. Chandler, M. Tan, J. Truscott, C.A. Garcia
Journal: Journal of Thoracic Oncology (2025)
66P: Long-term follow-up of limertinib (ASK120067) in patients with locally advanced or metastatic EGFR T790M NSCLC: A multicentre, single-arm, phase IIb study
Authors: L. Wu, B. Li, Y. Fan, Q. Shi, K. Li, J. Fang, G. Chen, Y. Liu, Z. He, Y. Ji, T. Zhou, R. Yang, Z. Li, K. Gu, Y. Pan, Z. Pan, H. Zhang, Y. Bai, D. Jiang, Y-K. Shi
Journal: Journal of Thoracic Oncology (2025)
73P: Real-world post-progression analysis of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Authors: J. Zhou, L. Shen, D. Lv, K. Tang, D. Zhu, Y. Zhao, K. Wang, Y. Wang, L. Xing, J. Cui, L. Ding, X. Shi, J. Zheng, J. Zhou
Journal: Journal of Thoracic Oncology (2025)
68P: Survival impact of immunotherapy(IO) after chemo-failure in EGFR-mutated NSCLCA post-hoc analysis of the Orient-31 trial
Authors: Z. Li, L. Wu, H. Jian, Y. Cheng, Q. Wang, J. Fang, Z. Wang, Y. Hu, M. Sun, L. Han, L. Miao, C. Ding, J. Cui, B. Li, Y. Pan, X. Li, F. Ye, A. Liu, K. Wang, S. Lu
Journal: Journal of Thoracic Oncology (2025)
71P: FIN-EGFRprint: A retrospective observational study to investigate treatments and outcomes in patients with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (aNSCLC) in Finland
Authors: A. Knuuttila, L. Nurmi, P. Vänni, J. Edwards, M. Ekblom, I. Luccarini, M. Silvoniemi
Journal: Journal of Thoracic Oncology (2025)
67P: A phase II study of sunvozertinib combined with anlotinib in EGFR-TKIs resistant EGFRm advanced NSCLC patients (WUKONG9)
Authors: J. Hu, Z. Liu, N. Ding, X. Tang, D. Yang, J. Li, D. Hou, X. Xu, Y. Zhang, Y. Song
Journal: Journal of Thoracic Oncology (2025)
70P: Amivantamab monotherapy in patients with pre-treated NSCLC with EGFR Exon 20 insertion mutations: Real-world data on efficacy and safety from the Italian biomarker ATLAS database
Authors: A. Passaro, M. Montrone, G. Pasello, M. Tiseo, M. Russano, H.J. Soto Parra, S. Grisanti, A. Bulotta, L.A. Muscarella, E. Bria, G. Metro, A. Delmonte, G. Lo Russo, D. Pozzessere, A. Veccia, F. Biello, M. Ramundo, U. Malapelle, S. Novello, F. Passiglia
Journal: Journal of Thoracic Oncology (2025)
57P: Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring 20ins and uncommon EGFR mutations (AIM)
Authors: W.F. Fang, Q. Bu, Q. Wang, W. Zhao, L. Wang, X. Dong, P. Chen, Z. Wen, J. Jia, G. Jiang, L. Zhang
Journal: Journal of Thoracic Oncology (2025)
63P: Osimertinib for patients with EGFRm non-small cell lung cancer: Analysis of the locally advanced/metastatic cohort (OSIREAL study)
Authors: D. Rodriguez Abreu, M.E. Lazaro, M.M. Lopez-Brea Piqueras, R. Bernabe Caro, L.A. Leon Mateos, O.J. Juan Vidal, R. López Castro, A. Azkárate Martınez, E. Arriola Aperribay, D. Aguiar Bujanda, S. Sequero Lopez, A. Artal, J.L. Gonzalez-Larriba, B. Massuti Sureda, A. Cardena, S. Ros Martinez, B. Hernandez Marin, Á. Callejo, A. Soto Simon, M. Dominguez
Journal: Journal of Thoracic Oncology (2025)
60P: The FIN-EGFR study: A retrospective observational study to investigate the treatment landscape and outcomes of early and advanced stage patients with EGFR mutated non-small cell lung cancer (NSCLC)
Authors: A. Knuuttila, L. Nurmi, M. Ekblom, A. Bonin, E.K. Heikkila, M. Silvoniemi
Journal: Journal of Thoracic Oncology (2025)
59P: Evaluating the effectiveness of amivantamab plus lazertinib in CHRYSALIS-2 vs EGFR TKI monotherapy in a matched real-world cohort of participants with atypical EGFR-mutated advanced NSCLC
Authors: P. Tomasini, Y. Wang, S-H. Lee, J. Cui, E. Felip, A. Spira, Y. Li, L. Wu, S. Michels, E. Ichihara, J. Neal, L. Demirdjian, C.S. Meyer, Y. Zhang, H. Kanakamedala, A. Louder, L. Trani, I. Leconte, M. Baig, B.C. Cho
Journal: Journal of Thoracic Oncology (2025)
58P: Subcutaneous (SC) after intravenous (IV) amivantamab in advanced NSCLC: Initial results from PALOMA-2
Authors: Sun Min Lim, J-Y. Han, J. Zhang, E. Mascarenhas, C.H. Andrade Teixeira, N. Girard, N. Peled, S. Scott, M. Gutierrez, A. Bulotta, J.L. Tan, T. Mekhail, D-A. Botesteanu, A. Alhadab, J. Mahoney, M. Wang, J. Zhang, J. Schuchard, M. Baig, F. Duarte
Journal: Journal of Thoracic Oncology (2025)
113P: Real-world treatment options for metastatic NSCLC patients following progression on chemo-immunotherapy
Authors: A. Cortellini, A. P B, K.S. Saini, R. George, C. Di Vincenzo, P. Nunes, V. Novikov, H. Huang, U. Batra, I. Chico, S. Ramkissoon, M. Russano, F. Pecci, M. Tiseo, L. Vidal, J. Rider, L. Cantini
Journal: Journal of Thoracic Oncology (2025)